Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	6/30/2005 3:32:25 AM
	Read Replies (1) of 3044

Millennium May Seek In-Licensing Deals In Next Year 06.29.05, 2:47 PM ET Credit Suisse First Boston maintained a "neutral" rating on Millennium Pharmaceuticals (nasdaq: MLNM - news - people ) after the biotech firm named a new chief executive. Millennium said Deborah Dunsire, previously head of the North American oncology division for Novartis (nyse: NVS - news - people ), will takeover for co-founder Mark Levin. "Dr. Dunsire plans to use the upcoming months to take a 'fresh look' at the company. This will include a review of the pipeline as well as opportunities for 'operational efficiencies'," said CSFB. The research firm maintained a $12 price target on the stock. "Much debate has centered on Millennium's ability to reach 2006 profitability without a re-acceleration of revenue growth or drastic cost cuts," it said. "We are more concerned about long-term earnings prospects and project 2008 earnings per share of just 13 cents. We believe Millennium will seek late-stage in-licensing opportunities over the next year in a bid to drive longer-term growth, at the potential expense of 2006 profits." forbes.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next